SUMMARY
Upon ligand binding, RIPK1 is recruited to tumor necrosis factor receptor superfamily (TNFRSF) and Toll-like receptor (TLR) complexes promoting prosurvival and inflammatory signaling. RIPK1 also directly regulates caspase-8-mediated apoptosis or, if caspase-8 activity is blocked, RIPK3-MLKL-dependent necroptosis. We show that C57BL/6 Ripk1 À/À mice die at birth of systemic inflammation that was not transferable by the hematopoietic compartment. However, Ripk1 À/À progenitors failed to engraft lethally irradiated hosts properly. Blocking TNF reversed this defect in emergency hematopoiesis but, surprisingly, Tnfr1 deficiency did not prevent inflammation in Ripk1 À/À neonates. Deletion of Ripk3 or Mlkl, but not Casp8, prevented extracellular release of the necroptotic DAMP, IL-33, and reduced Myd88-dependent inflammation. Reduced inflammation in the Ripk1 À/À Ripk3 À/À , Ripk1 À/À Mlkl À/À , and Ripk1 À/À Myd88 À/À mice prevented neonatal lethality, but only Ripk1 À/À Ripk3 À/À Casp8 À/À mice survived past weaning. These results reveal a key function for RIPK1 in inhibiting necroptosis and, thereby, a role in limiting, not only promoting, inflammation.
INTRODUCTION
Befitting its major inflammatory role, tumor necrosis factor (TNF) signaling via its receptor TNFR1 is highly regulated. In addition to driving the transcription of a host of inflammatory cytokines, TNF is also capable of initiating two cell death pathways, caspase-8-dependent apoptosis and RIPK1 kinase-dependent necroptosis (Vandenabeele et al., 2010) . However, in the vast majority of cells, TNF does not induce cell death. It is believed that this is because the same IkB kinase (IKK)/mitogen-activated protein kinase (MAPK)-dependent increase in transcription that drives inflammatory cytokine production also upregulates antiapoptotic genes that inhibit the activation of caspase-8. Cellular FLICE-like inhibitory protein (cFLIP), a caspase-8 inhibitor, is chief among these antiapoptotic genes, and in the absence of cFLIP, TNF rapidly induces caspase-8-dependent apoptosis (Panayotova-Dimitrova et al., 2013; Piao et al., 2012) . RIPK1 is believed to play an essential role in the activation of IKK/MAPK and in the transcription of cFLIP (Ea et al., 2006; Gentle et al., 2011; Micheau et al., 2001) . In this role, it behaves as a structural element that is ubiquitylated by cellular inhibitor of apoptosis proteins (cIAPs) and linear ubiquitin chain assembly complex (LUBAC), and the ubiquitin chains decorating RIPK1 can recruit and trigger the activation of NF-kB and MAP kinases (Schmukle and Walczak, 2012; Wertz and Dixit, 2010) . Consistent with an essential role for cFLIP in regulating caspase-8, cFlip/Cflar knockout mice die at embryonic stage E10.5 (Yeh et al., 2000) .
Activation of caspase-8 by TNF occurs in a secondary cytoplasmic signaling complex that contains the protein Fas-associated protein with death domain (FADD) (Micheau and Tschopp, 2003) . The death effector domain of FADD causes the oligomerization and autoactivation of caspase-8 (Wertz and Dixit, 2010) . It is therefore surprising that Fadd and Casp8 knockout mice both die at the same embryonic stage, from the same defects, as the cFlip/Cflar-deficient mice (Varfolomeev et al., 1998; Yeh et al., 1998) . Because Fadd À/À Ripk3 À/À and Casp8
Ripk3
À/À mice survive to adulthood (Kaiser et al., 2011; Oberst et al., 2011; Dillon et al., 2012) , it is supposed that, in the absence of cFLIP, a lethal apoptotic pathway is initiated and that, in the absence of caspase-8 activation, an alternative lethal necroptotic RIPK1/ RIPK3-dependent pathway occurs. Therefore, current models for TNF signaling indicate that RIPK1 plays very important roles in two branches of the TNFR1 response: to inhibit apoptosis via cFLIP and to cause necroptosis in a RIPK1-kinase-dependent manner (Vandenabeele et al., 2010) . Furthermore, RIPK1 may play similar roles in other innate immune signaling complexes, including Toll-like receptor (TLR) and MAVS/RIG-I (Kaiser et al., 2013; Meylan et al., 2004; Michallet et al., 2008) . The pivotal role for RIPK1 in regulating outcomes from these innate immune signaling complexes makes the phenotype of the Ripk1 À/À mice remarkable.
In distinction to other regulators of the TNF pathway that die at embryonic stage E10.5, Ripk1 À/À mice on a mixed 129/Sv C57BL/6 background die within 3 days of birth (Kelliher et al., 1998) . However, survival of the Ripk1 À/À mice was prolonged to 12 days after birth by Tnfr1 deletion (Cusson et al., 2002) . Although Tnfr1 deletion provides protection from Ripk1
perinatal lethality, it is incomplete, and the reason for the death of Ripk1 À/À mice remains enigmatic. We therefore sought to determine the cause of this lethality. We show that, on a C57BL/6 background, Ripk1 À/À mice die at birth from systemic inflammation, but they can be partially protected by deleting Myd88 and thereby blocking IL-1 family and TLR inflammatory signaling. Furthermore, the embryonic lethality of Casp8 À/À mice can be prevented by loss of RIPK1; however, loss of caspase-8 cannot protect Ripk1 À/À mice from systemic inflammation and perinatal death. On the other hand, loss of the essential effectors of necroptosis, RIPK3 or MLKL, provides protection to Ripk1 À/À mice from systemic inflammation but fails to correct a lethal intestinal defect. Ripk1 deficiency-induced inflammation was associated with the release of IL-33, suggesting that this cytokine is a necroptotic danger-associated molecular pattern (DAMP) in vivo. Finally, we show that Ripk1
Casp8
À/À mice were protected from inflammation and intestinal disruption and are viable and fertile. These results add to our understanding of the role of RIPK1 in regulating cell-deathinflammatory signaling pathways and demonstrate that necroptotic cell death can initiate a lethal inflammatory cascade.
RESULTS

RIPK1 Deficiency Results in Perinatal Lethality
Marked by Systemic Cell Death Ripk1 À/À mice die within 3 days of birth on a mixed 129/Sv C57BL/6 background (Kelliher et al., 1998) . After more than ten crosses with C57BL/6 mice, we found that Ripk1 À/À mice develop severe multiorgan inflammation in utero and die within minutes of birth or Caesarean section. Ripk1 À/À neonates appeared edematous and cyanotic ( Figure 1A ). The rapid cyanosis of Ripk1 À/À neonates and labored breathing ( Figure 1B) suggests that respiratory failure is the major cause of perinatal lethality. Cell death was the most striking histopathological finding with large necrotic regions in the liver and thymus (Figure 1C and Figure S1 and Table S2 available online) and cleaved caspase-3 (CC3)-positive cells in lung, liver, intestine, and thymus ( Figures 1D and S1 ). CC3 and -8 were also detectable in plasma from Ripk1 À/À , but not Ripk1 +/+ neonates ( Figure 1E ).
Ripk1
À/À neonates had epidermal hyperplasia with no signs of CC3 ( Figures 1C and 1D ). Keratin-6 expression, which is normally confined to hair follicles in healthy skin, was also aberrantly expressed in Ripk1 À/À epidermis ( Figure 1C ).
À/À Neonates Exhibit Systemic Inflammation
Inflammatory cytokines were upregulated in the skin (Figure 2A ), plasma ( Figure 2B ), liver, lung, and intestine ( Figure S2A ). Ripk1 À/À neonates also had severe anemia and neutrophilia ( Figures 2C-2E , S2B, and S2C), which is consistent with the elevated levels of proinflammatory cytokines and chemokines in the plasma; granulocyte colony-stimulating factor (G-CSF) was elevated >10 5 -fold (Figures 2B and S2A) . Surprisingly, given these results, the number of leukocytes in various tissues was reduced ( Figures 2F and S1 ).
RIPK1 Is Required for Normal Hematopoiesis
To assess whether the inflammatory Ripk1 À/À phenotype was transferable, we transplanted lethally irradiated mice with wildtype (WT) or Ripk1 À/À fetal liver cells taken at embryonic day (E) 13.5. There was no evidence of inflammatory disease in recipient mice ( Figure S3A) ; however, Ripk1 À/À hematopoietic cells failed to engraft efficiently, with deficits in both myeloid and lymphoid lineages evident 8 weeks posttransplant (Figures 3A and 3B) . Furthermore, at 14 and 26 weeks, an almost-complete loss of myeloid and lymphoid donor Ripk1 À/À cells was observed (Figure 3A) . Embryonic WT progenitor cells express RIPK1 (Figure S3B) , and Ripk1 À/À embryos had a normal hematopoietic progenitor cell compartment at E13.5 but a decrease in granulocyte-macrophage progenitors and megakaryocyte-erythroid progenitors at P0 ( Figure 3C ). Furthermore, the functional potential of Ripk1 À/À embryonic progenitors remained normal ex vivo ( Figure 3D ). This suggests that the deficits observed in Ripk1 À/À hematopoietic progenitor cells at P0 are a reflection of the systemic inflammation in these mice, but this does not account for the deficit when fetal liver cells are used to reconstitute mice ( Figure 3C ). (Figure S3C) . Similarly, the yield of macrophages derived from Ripk1 À/À fetal liver was reduced ( Figure S3D ), and they were sensitive to TNF-induced cell death ( Figure S3E ). Finally, we repeated the engraftment experiments with a TNF blocking antibody that rescued the reconstitution defect ( Figure 3H ). These reconstituted mice did not show signs of inflammation. Together, these results suggest that loss of RIPK1 sensitizes hematopoietic cells, including progenitors, to TNF-induced cell death, but this intrinsic defect, in isolation, is insufficient to initiate inflammatory disease.
Loss of TNFR1, FasL, or Caspase-8 Does Not Prevent Ripk1 À/À Lethality
To examine the contribution of apoptotic signaling to Ripk1 À/À neonatal lethality, we generated Ripk1 À/À Tnfr1 À/À mice. In contrast to the partial suppression previously observed with Tnfr1 deletion on the mixed 129/Sv background (Cusson et al., 2002) , loss of Tnfr1 did not provide meaningful protection on the C57BL/6 background, and Ripk1
within half an hour of birth ( Figure 4A ). Combined deficiency of TNF and the cell death ligand, FasL, also failed to prevent the Ripk1 À/À lethality ( Figures 4A and 4B ).
To test the direct contribution of the extrinsic apoptotic pathway to the Ripk1 À/À phenotype, we generated Ripk1
Casp8
À/À mice. Despite the fact that loss of caspase-8 results in lethality at E10.5 (Varfolomeev et al., 1998) suppressed in Ripk1
neonates, respectively, and correlated with the lack of CC3 in the intestine ( Figures 4F and S4C ).
RIPK3 and MLKL Deficiency Prevents
According to prevailing models, loss of RIPK1 should block necroptosis. However, the fact that loss of Casp8, and therefore apoptosis, did not protect Ripk1 À/À mice from perinatal lethality caused us to re-examine this. We therefore hypothesized that excessive necroptotic cell death occurs in Ripk1 À/À neonates and generated Ripk1 À/À Ripk3 À/À and Ripk1 À/À Mlkl À/À mice to test this. Remarkably, these mice appeared normal at birth (Figure 5A) . Cell death that was visible by hematoxylin and eosin staining (H&E) was also reduced in these mice, and CC3 was undetectable in their plasma and reduced in all organs except the intestine (Figures 5B, 5C, and S5F). Consistent with necroptotic cell death driving inflammation, Ripk1
Ripk1
À/À Mlkl À/À mice mostly had normal keratin-6 and -14 expression (Figures 5D and S5G and Table S3 ) and normal white and red blood cell levels at P0 and P3 (Figures 5E and S5B) , and leukocyte levels in tissues were restored ( Figure S5F ). These mice also had reduced inflammatory cytokine levels at these time points (Figures 5F and S5D) compared to the S5E ). We sought to correlate these changes with molecular markers of apoptosis and necroptosis. Remarkably, RIPK3, MLKL, and cFLIP levels were all elevated in Ripk1 À/À skin when compared to WT controls (Figures 5I and 5J) . This elevated cFLIP could inhibit caspase-8-induced apoptosis and, together, with the elevated levels of the necroptotic effectors, provides a potential explanation for the suppression of Ripk1 À/À keratinocyte hyperplasia by combined loss of MLKL or RIPK3.
À/À Systemic Inflammation Is Not Driven by the Inflammasome Because pyroptosis, a caspase-1-dependent cell death, can result in systemic inflammation and was suggested to be dependent on RIPK3 in BMDM and BMDC models, we tested the possibility that the inflammasome is activated in Ripk1
mice. Lipopolysaccharide (LPS) priming in Ripk1 À/À fetal liverderived macrophages (FLDM), without an inflammasome stimulus, resulted in secretion of low levels of cleaved IL-1b and caspase-1 ( Figures 6A and S6A ). In agreement with earlier reports (Kang et al., 2013; Vince et al., 2012) All graphs show mean + SEM; *p % 0.05 and **p % 0.01.
importance of these DAMPs in vivo is unknown (Kaczmarek et al., 2013 and Ripk1
Ripk3
À/À mice, indicating an important role for necroptotic death in IL-33 production ( Figure 6G ).
MyD88 is an essential component of IL-1, IL-33, and a subset of TLR signaling complexes (Beutler et al., 2006) . We therefore hypothesized that Myd88 deficiency could provide a survival advantage to Ripk1 À/À mice by reducing these inflammatory pathways. In contrast to the lack of suppression of the Ripk1
phenotype observed with Tnfr1 deletion, Ripk1
onates appeared relatively normal at birth and had mild to no edema ( Figure 6H ). Unfortunately, like the Ripk3 À/À and Mlkl À/À crosses, the mice failed to thrive and only survived about 4 days from birth ( Figure S6B ). Deletion of Myd88 reduced neutrophilia, prevented the anemia, and dramatically reduced the inflammation seen in Ripk1 À/À neonates ( Figures 6I, 6J , S6C, and S6D). At P0, epidermal hyperplasia and CC3 in the plasma were still observed in Ripk1 À/À Myd88 À/À neonates (Figures 6K   and S6F and Table S1 ). Nevertheless, in surviving mice (P3), Myd88 loss prevented the epidermal hyperplasia, but not the intestinal CC3 and the low blood glucose seen in Ripk1
neonates ( Figures 6L, 6M , S6E, and S6F). 
Caspase-8 Deficiency Prevents
Ripk1
The areas of enterocyte cell death and CC3-positive cells in Ripk1
Ripk1
À/À Mlkl À/À , and Ripk1
mice, which progressively worsen from birth to P3, raised the possibility that defective gastrointestinal function may be the underlying cause of death in these compound knockout mice. One obvious possibility was that bacterial colonization after birth leads to TNF production and intestinal cell death; however, Ripk1
Ripk3
À/À mice generated in an abiotic environment were not protected from early death (Table S1 ). To test whether the loss of gastrointestinal function was the result of excessive caspase-8-dependent apoptosis in the Ripk1
À/À and Ripk1 À/À Mlkl À/À mice, as suggested by the prevention of the intestinal pathology in the Ripk1
mice. These mice were viable and fertile and put on weight like their WT counterparts ( Figures 7A and S7A ). CC3 was absent from the intestine and plasma, and the mice displayed none of the Ripk1 À/À inflammatory pathology ( Figures 7B, 7C , S7B, S7C, and S7F-S7I and Table S3 ). Furthermore, unlike Ripk1
Casp8
À/À cells were not outcompeted by WT cells in a competitive transplant assay ( Figures  7D and S7J ). When aged, these mice developed the lymphoproliferative syndrome ( Figures 7E-7G , S7D, and S7E) seen in Casp8 À/À Ripk3 À/À mice (Kaiser et al., 2011; Oberst et al., 2011 Figure 7G ).
DISCUSSION
We show that C57BL/6 Ripk1 À/À neonates succumb to a celldeath-induced inflammatory phenotype with multiorgan pathology (Table S1 ). Ripk1 À/À mice on a mixed 129/Sv C57BL/6 background died within 3 days of birth (P3) (Kelliher et al., 1998) , but by the fourth backcross of mixed background 
Ripk1
À/À to C57BL/6 mice, we were unable to recover viable knockout mice at P0. The 129/Sv strain is mutant for caspase-11, and some of the phenotype previously ascribed to loss of caspase-1, a closely linked gene in the same 9qA1 chromosomal location, is due to the loss of caspase-11 (Kayagaki et al., 2011) . However, RIPK1 is on murine chromosome 13, and therefore, given the extent of the backcross needed to reveal the perinatal lethality, functional caspase-11 is unlikely to be the modifier. The importance of the genetic background is emphasized by the role of Tnfr1 in the Ripk1 À/À phenotype. C57BL/6 129/Sv Ripk1
mice survive up to 12 days after birth (Cusson et al., 2002) . Remarkably, however, given the focus on the role of RIPK1 in TNF signaling, Ripk1 À/À lethality at birth was not prevented at all by deletion of Tnfr1 on a C57BL/6 background, although the disrupted intestinal phenotype was. Cusson et al. (2002) reported that Ripk1 À/À thymocytes were reduced 6 weeks after transplant of Ripk1 À/À fetal liver cells into lethally irradiated mice and died in a TNFR2-dependent manner, but B and myeloid cell numbers appeared normal. We found that B-and T-lymphoid and neutrophil numbers were reduced 8 weeks posttransplant in the absence of RIPK1. Furthermore, at this time, there were deficits in progenitor cell numbers, and, by 14 weeks, profound defects in the ability of Ripk1 À/À cells to reconstitute all hematopoietic compartments became apparent. During engraftment, a model of emergency hematopoiesis, hematopoietic stem cells must rapidly generate large numbers of mature cells for the recipient to survive. Our results demonstrate that TNF, which was shown to be upregulated during emergency hematopoiesis (Weill et al., 1996) , plays a role in the Ripk1 À/À engraftment defect because administration of neutralizing TNF antibodies suppressed the emergency hematopoietic defect. Similarly, loss of caspase-8 also causes B, T, and progenitor cell defects in Rag1 À/À reconstituted mice (Kang et al., 2004 that the hematopoietic compartment, in isolation, is a major initiator of the inflammatory phenotype. Despite the fact that TNF/TNFR1 signaling does not play a significant role in Ripk1 À/À lethality, RIPK1 clearly has a protective role in TNF signaling. In this role, it provides a platform for recruitment of kinases that are required to activate NF-kB and thereby upregulate antiapoptotic proteins, principally cFLIP, to prevent activation of caspase-8 and -3 and apoptosis (Schmukle and Walczak, 2012; Wertz and Dixit, 2010) . The power of genetic experiments is that they test such models in global terms. Loss of RIPK1 in the mouse leads to massive cell death, associated with CC3 and -8; therefore, RIPK1 clearly plays a protective role during embryogenesis. However, there are important exceptions; for example, a TNF-dependent checkpoint exists at embryonic stage E10.5 (Dillon et al., 2014 [this issue of Cell] ), and in the absence of cFLIP, mice die at this stage (Yeh et al., 2000) . Because loss of RIPK1 does not lead to embryonic death at E10.5, then RIPK1 is not required to protect against TNF-driven lethality at E10.5. Furthermore, we can conclude that production of cFLIP at E10.5 is independent of RIPK1. More surprisingly still, loss of RIPK1 results in dramatic upregulation of cFLIP levels in the skin, turning the accepted model on its head in this tissue. In other tissues, the cFLIP/RIPK1 axis may play a more important role. Conditional deletion of cFlip in intestinal epithelial cells (Piao et al., 2012) led to uncontrolled apoptosis and perinatal lethality (P2), which was prevented by deletion of Tnfr1. Although Tnfr1 deletion did not prevent early lethality of Ripk1 À/À mice, we observed reduction in cell death and pathology in the large intestine. Thus, the TNF/TNFR1/RIPK1 signaling axis plays an important role in the intestine, but the source of TNF is unknown. TNF/TNFR1 knockout mice have defective Peyer's patch formation (Korner et al., 1997) , thus there might be a local, developmentally regulated source of TNF. Alternatively, the intestine of P0 Ripk1 À/À mice may be exquisitely sensitive to systemic TNF circulating in these mice. Ripk1
Ripk3
À/À , and Ripk1
Mlkl À/À mice survive beyond birth and become colonized by bacteria. Thus, in these mice, it is possible that host-microbial interactions generate TNF. However, Ripk1
À/À mice raised in an abiotic environment had no survival advantage, indicating that host-microbiome interaction is not a significant factor in the lethality at P4. Similarly to Tnfr1 deletion, Casp8 deletion reduced cell death and pathology in the large intestine of Ripk1 À/À mice. In agreement with our interpretation that the excessive intestinal apoptosis kills 
Ripk1
À
RIPK1 not only protects from TNF induced killing, but if caspase-8 activity is inhibited, then it is believed to be required for TNF-or TLR-induced necroptosis in a kinase-dependent manner. In part, this idea has arisen because the RIPK1 kinase inhibitor, necrostatin, blocks necroptosis, and therefore, RIPK1 kinase activity and necroptosis have become synonymous. A requirement for RIPK1 in necroptosis is suggested in the situation of the embryonic lethality of Casp8 À/À mice at embryonic stage E10.5 because loss of Ripk1, like loss of Ripk3, prevents this lethality. However, the Ripk1 À/À mouse shows that RIPK1
is not a universal requirement for necroptosis; if it were, then Ripk1 À/À Casp8 À/À mice would be completely defective in both apoptotic and necroptotic pathways and phenocopy the viable 
Ripk3
À/À Casp8 À/À mice. However, combined deletion of Casp8 and Ripk3 is required to protect Ripk1 À/À mice, suggesting that RIPK3-dependent necroptotic cell death can be activated in a RIPK1-independent manner. The fact that the Ripk1
further support for the idea that there is physiological RIPK1-independent necroptosis. Such RIPK1-independent necroptosis is consistent with reports that oligomerization and activation of RIPK3 may be driven by spontaneously high RIPK3 levels or by another RHIM-containing protein such as DAI or TRIF (Feoktistova et al., 2011; Moujalled et al., 2013; Upton et al., 2010) . Counterintuitively keratinocyte hyperplasia is an excellent marker of excessive cell death in the skin as seen in the epidermal keratinocyte-specific knockouts (EKO): cFlip EKO , Ikbkb EKO , Fadd EKO , Casp8 EKO , and Sharpin mutant mice (Bonnet et al., 2011; Gerlach et al., 2011; Panayotova-Dimitrova et al., 2013; Pasparakis et al., 2002) . Ripk1 À/À mice have a similar skin phenotype to these mice. Not only are MLKL and RIPK3 upregulated in the skin of Ripk1 À/À mice, but cFLIP is as well.
Combined upregulation of these necroptotic effectors and the caspase-8 inhibitor cFLIP strongly suggests that Ripk1 À/À skin cells are dying a necroptotic cell death, and this conclusion is reinforced by the fact that the Ripk1 À/À skin phenotype is largely prevented by loss of Ripk3 or Mlkl, but not Casp8. Clearly, however, this necroptotic cell death is caused by loss of, and is not dependent upon, RIPK1.
Loss of RIPK3 prevents the early embryonic lethality observed in caspase-8 knockout mice (Kaiser et al., 2011; Oberst et al., 2011) , suggesting that loss of caspase-8 results in unchecked RIPK3-dependent necroptosis. Although RIPK3 and caspase-8 are best known as cell death mediators, both have emerged as direct regulators of the inflammasome and other inflammatory signaling pathways (Kang et al., 2013; Vince et al., 2012) . Therefore, an alternative explanation for the E10.5 lethality is that absence of caspase-8 leads to an increase in RIPK3-dependent inflammatory cytokine production and death. The late lethality of Ripk1 knockout mice has facilitated delineation of the relative importance of these two functions because Ripk1
mice have significantly less death and inflammation, whereas the Ripk1 À/À Myd88 À/À mice have reduced inflammation but not dramatically reduced cell death. Further support for the idea that necroptosis can be a driver of lethal inflammation comes from the fact that Ripk1
mice phenocopy each other with dramatically reduced inflammation. MLKL functions downstream of RIPK3 in the necroptotic pathway (Moujalled et al., 2013; Murphy et al., 2013; Sun et al., 2012; Zhao et al., 2012) and may be a direct necroptosis effector (Chen et al., 2014) . Although MLKL may have a role in cytokine production mediated by the inflammasome in the absence of caspase-8 (Kang et al., 2013) , it does not in response to Smac mimetics (Wong et al., 2014) or a TLR ligand ( Figure S5C ). Although Ripk1 À/À FLDMs showed RIPK3-dependent spontaneous activation of the inflammasome, it was at very low levels compared to a conventional NLRP3 inflammasome stimulus such as ATP. Furthermore, the systemic inflammation in the Ripk1 À/À mice was not associated with markers of inflammasome activation. Taken together, we believe our data favor the interpretation that necroptosis induces inflammation. An outstanding question in the field is the nature of necroptotic DAMPs (Kaczmarek et al., 2013) . Because the Ripk1 À/À inflammatory phenotype is rampant before birth, in a sterile embryonic environment, the DAMPs must be endogenous in origin. We observed high numbers of apoptotic cells throughout the Ripk1 À/À embryos, and contents from these uncleared cells could feasibly generate DAMPs. However, we do not favor this hypothesis because compound Ripk1
not protected from inflammation. We favor the hypothesis that RIPK1-independent necroptotic cell death is the source of DAMPs because both Ripk1 À/À Ripk3 À/À and Ripk1
are protected from the lethal inflammatory disease. HMGB1 is released from necroptotic cells in vitro and has a role in certain in vivo inflammation models (Scaffidi et al., 2002) , suggesting that it is a necroptotic DAMP. However, we did not observe release of HMGB1 into plasma above control levels. Two other DAMPs that have been associated with necroptosis, IL-1a and IL-33 (Kaczmarek et al., 2013) , were detected in the plasma of Ripk1 À/À mice. IL-33 was expressed at high levels in the intestine and skin of Ripk1 À/À . Furthermore, IL-33 was detected in a processed form that corresponded to a previously reported neutrophil cleaved bioactive form (Lefranç ais et al., 2012) . IL-1a is not released during apoptosis (Cohen et al., 2010) , and IL-33 was suggested to be cleaved to a nonactive form ($p25 and $p10) during apoptosis by caspase-3 (Lü thi et al., 2009 Our findings reveal an essential physiological role for RIPK1 in immune homeostasis and emergency hematopoiesis. Remarkably, direct regulation of TNFR1 by RIPK1 is not important to prevent inflammation or cell death in the embryo, except in a tissue-specific manner. RIPK1 is required for TNF-induced necroptosis at E10.5; however, surprisingly, in later stages of embryogenesis, RIPK1 plays an essential role in inhibiting necroptosis. The fact that the Ripk1
À/À mice provides the strongest evidence so far that, in the context of inflammatory signaling, the role of RIPK3 in generating necroptotic DAMPs is at least as important as its direct role in promoting inflammatory cytokine production. We therefore propose that loss of RIPK1 inhibition of RIPK3/MLKLdependent necroptosis promotes the production and release of necroptotic DAMPs such as IL-1a and IL-33, revealing a key function for RIPK1 in limiting, not only promoting, inflammation.
EXPERIMENTAL PROCEDURES Mice
All mice were backcrossed to C57BL/6J mice for >10 generations or generated on a C57BL/6J background. Mlkl À/À mice were generated as described . Mice obtained by Caesarean section at E19.5 or a few hours after natural birth were designated P0. Pregnant mice were prepared for Caesarean delivery by progesterone injection at E17.5 and E18.5. The relevant Animal Ethics Committee approved all experiments.
Histology and Immunofluorescence
Embryos were fixed in 10% neutral buffered formalin, paraffin embedded, and sectioned for routine histology staining (H&E). For skin immunofluorescence, paraffin sections were dewaxed, subjected to heat-induced epitope retrieval (HIER) with citrate buffer, blocked in 3% goat serum, permeabilized with 0.3% Triton X-100, and stained with keratin 6 (Covance), keratin 14, and goat anti-rabbit alexa-594 (Invitrogen) antibodies. Nuclei were visualized using Hoechst (Invitrogen). For tissue immunohistochemistry, sections were dewaxed and subjected to antigen retrieval in trypsin buffer (F4/80) or HIER with citrate buffer (CD45, CC3) and stained with the following antibodies: anti-CC3 (Cell Signaling Technology 9661), anti-CD45 (BD), anti-F4/80 (generated in-house), goat anti-rabbit biotinylated, and goat anti-rat biotinylated antibodies (Vector Laboratories). Images were taken using a DP72 microscope and cellSens Standard software (Olympus).
Cytokine Bioplex Assay
Cytokines were measured by Bioplex Pro mouse cytokine 23-plex assay (BioRad) according to manufacturer's instructions. Where a value was above or below the reference range, it was assigned the value of the highest or lowest standard, respectively. Lysates were made by homogenizing organs in icecold protein DISC lysis buffer followed by protein level normalization using a BCA assay (Thermo Scientific). Skin samples were obtained from mice delivered by Caesarean at E20.5. Progenitor Cell Analysis Clonal cultures of hematopoietic cells were performed as described (Croker et al., 2004) . For some experiments, sorted lineage À cKit + E18.5 liver cells were cultured in 100 ng/ml SCF + 10 ng/ml IL-3 + 4U/ml EPO with PBS, 10 ng/ml TNF, or 200 ng/ml Fc-FasL for 24 hr. To analyze progenitor viability, lineage À cKit + cells were monitored by flow cytometry with PI.
Immunoblotting Organ lysates were made by homogenizing whole intestine or dorsal skin from P0 mice in ice-cold DISC lysis buffer containing cOmplete protease inhibitor cocktail (Roche), 20 mM MG132, 5 mM N-ethylmaleimide, 10 mM sodium fluoride, 5 mM b-glycerophosphate, 2 mM sodium pyrophosphate, 2 mM sodium pervanadate, and 1 mM sodium molybdate. Insoluble component was spun down, and supernatants were quantified with a BCA assay (Thermo Scientific). Supernatants were boiled with SDS reducing sample buffer. Plasma samples were diluted with PBS and boiled with SDS reducing sample buffer. Organ lysates and plasma samples were run on 4%-12% Bis-Tris gels (Invitrogen). Fetal liver lineage À cKit + cells were lysed as previously described (Croker et al., 2004) . 
Hematology and Flow Cytometry
Automated cell counts were performed on blood collected from the retroorbital plexus into Microtainer tubes containing EDTA (Sarstedt) using an Advia 2120 hematological analyzer (Siemens). For further analysis, blood smears were performed and assessed following May-Grü nwald Giemsa staining. Flow cytometric analysis of hematopoietic cells was performed on a BD Biosciences LSRFortessa cell analyzer and analyzed using FlowJo software (Treestar). Ly5.1 and Ly5.2 expression determined the contribution of donor and recipient cells. Blood glucose was quantified using an Accu-Chek Performa (Roche) glucometer.
Bone-Marrow-Derived Macrophages and Fetal-Liver-Derived Macrophages Macrophages were generated by culturing cell suspensions generated from bone marrow (for bone-marrow-derived macrophages, BMDMs) or E14.5 fetal livers (for fetal-liver-derived macrophages, FLDM) and differentiated for 7 days in M-CSF L929 conditioned media. For cell death assays, FLDMs were treated with recombinant human Fc-TNF and QVD (SM Biochemicals LLC) as indicated for 24 hr and then subjected to cell death analysis by flow cytometry quantification of PI uptake using a FACSCalibur (BD Biosciences). For the inflammasome assays, FLDMs were plated at 50-100,000 cells per well in a 96 well plate and stimulated with LPS (20 ng/ml) for 6-8 hr followed by ±5 mM ATP for 40-60 min. Lysates and supernatants were analyzed by western blotting. Supernatants were analyzed by ELISA (IL-1b, R&D Systems). Controls for caspase-1 and IL-1b detection in plasma and organs using western blotting were generated using BMDMs treated as above or pretreated with LPS for 2 hr followed by Smac mimetic treatment for 6 hr (GT12911, TetraLogic Pharmaceuticals). For Figure S6C , BMDMs of indicated genotypes (n = 3) were treated with LPS (20 ng/ml) for 9 hr, and IL-6 levels in supernatants were analyzed by ELISA (eBioscience).
Statistics
Unless otherwise specified, data are presented as mean + 1 SEM. Comparisons were performed with a Student's t test. 
